These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 7990857)

  • 21. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease.
    Greenamyre JT; Eller RV; Zhang Z; Ovadia A; Kurlan R; Gash DM
    Ann Neurol; 1994 Jun; 35(6):655-61. PubMed ID: 8210221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome.
    Chazot PL
    Curr Opin Investig Drugs; 2007 Jul; 8(7):570-9. PubMed ID: 17659477
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of multiple doses of milacemide in the treatment of senile dementia of the Alzheimer's type.
    Cutler NR; Fakouhi TD; Smith WT; Hendrie HC; Matsuo F; Sramek JJ; Herting RL
    J Geriatr Psychiatry Neurol; 1993; 6(2):115-9. PubMed ID: 8512628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pallidotomy improves motor responses and widens the levodopa therapeutic window in Parkinson's disease.
    Skalabrin EJ; Laws ER; Bennett JP
    Mov Disord; 1998 Sep; 13(5):775-81. PubMed ID: 9756145
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MAO-B inhibitors for the treatment of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S38-44. PubMed ID: 12211138
    [No Abstract]   [Full Text] [Related]  

  • 27. Monoamine oxidase-B, monoamine oxidase-B inhibitors, and Parkinson's disease. A role for superoxide dismutase?
    Sandler M; Glover V; Clow A; Jarman J
    Adv Neurol; 1993; 60():238-41. PubMed ID: 8420141
    [No Abstract]   [Full Text] [Related]  

  • 28. Excitotoxicity and new antiglutamatergic strategies in Parkinson's disease and Alzheimer's disease.
    Koutsilieri E; Riederer P
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S329-31. PubMed ID: 18267259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980.
    Bravi D; Davis TL; Mouradian MM; Chase TN
    Mov Disord; 1993 Apr; 8(2):195-7. PubMed ID: 8097280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of glutamate in the pathophysiology of Parkinson's disease.
    Blandini F; Greenamyre JT; Nappi G
    Funct Neurol; 1996; 11(1):3-15. PubMed ID: 8936453
    [No Abstract]   [Full Text] [Related]  

  • 31. What has been learnt from study of dopamine receptors in Parkinson's disease?
    Hurley MJ; Jenner P
    Pharmacol Ther; 2006 Sep; 111(3):715-28. PubMed ID: 16458973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease.
    Syed N; Murphy J; Zimmerman T; Mark MH; Sage JI
    Mov Disord; 1998 Mar; 13(2):336-8. PubMed ID: 9539350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rasagiline as a therapy for Parkinson's disease (PD).
    Hermanowicz N
    Am J Geriatr Pharmacother; 2007 Jun; 5(2):174-5; author reply 175-6. PubMed ID: 17719520
    [No Abstract]   [Full Text] [Related]  

  • 34. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
    Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No relevance to Parkinson's.
    Hefti F; Denton TL; Beck KD; Michel PP
    Nature; 1991 Aug; 352(6336):573. PubMed ID: 1830925
    [No Abstract]   [Full Text] [Related]  

  • 36. New drug treatment for Parkinson's disease.
    FDA Consum; 2006; 40(4):7. PubMed ID: 17245831
    [No Abstract]   [Full Text] [Related]  

  • 37. Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.
    Blanchet PJ; Grondin R; Bédard PJ
    Mov Disord; 1996 Jan; 11(1):91-4. PubMed ID: 8771074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical pharmacology of MAO inhibitors: safety and future.
    Yamada M; Yasuhara H
    Neurotoxicology; 2004 Jan; 25(1-2):215-21. PubMed ID: 14697896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms of motor complications in treatment of Parkinson's disease.
    Kumar A; Huang Z; de la Fuente-Fernández R
    Adv Neurol; 2003; 91():193-201. PubMed ID: 12442678
    [No Abstract]   [Full Text] [Related]  

  • 40. An open study with reversible MAO-A inhibitors in complicated Parkinson's disease.
    Ruggieri S; Fabbrini G; Bramante L; DePandis F; Stocchi F; Barbanti P; Vacca L; Manfredi M
    Adv Neurol; 1996; 69():595-8. PubMed ID: 8615185
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.